19 October 2009
Influence of selected angiotensin-converting enzyme inhibitors on alloxan-induced diabetic cataract in rabbitsAnna JableckaADFG, Ewa CzaplickaABDF, Jan OlszewskiABD, Pawel BogdanskiBCDEF, Hanna KraussDEG, Iwona SmolarekCDE
Med Sci Monit 2009; 15(11): BR334-338 :: ID: 878235
Hyperglycemia enhances cataractogenesis. Elevated glucose level is commonly accompanied by arterial hypertension, for which angiotensin-converting enzyme (ACE) inhibitors (ACEIs) are a widely used intervention. ACE inhibitors exert some endothelial pleiotropic actions and can beneficially modulate glucose control and some other metabolic pathways. The purpose of this study was to evaluate the effect of ACEIs on cataract formation in experimental alloxan-induced diabetes in rabbits and assess the role of the reactive function group of the ACEIs in this process.
Material and Method
Two study and two control groups of rabbits were examined. In the study groups and in one of the control groups, diabetes was induced by alloxan. The study groups were assigned to receive captopril or enalapril for six months; the controls received distilled water. Glucose concentration was monitored with a glucometer. A biomicroscope and an ophthalmoscope were used to evaluate lens opacity and cataractogenesis.
Six-month administration of ACEI to rabbis resulted in a delay of diabetic cataractogenesis. The rate of cataract formation was significantly lower in the group treated with captopril than in the enalapril group. A difference in morphology of lens opacity formation between the two study groups was observed.
ACEIs delay diabetic cataractogenesis in an experimental animal model. The ACEI functional groups have different influences on the pattern and rate of lens opacity.
Keywords: Diabetes Mellitus, Experimental - drug therapy, Enalapril - therapeutic use, Cataract - drug therapy, Captopril - therapeutic use, Blood Glucose - drug effects, Angiotensin-Converting Enzyme Inhibitors - therapeutic use, Rabbits
12 September 2022 : EditorialEditorial: Treatment with Dual Incretin Receptor Agonists to Maintain Normal Glucose Levels May Also Maintain Normal Weight and Control Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
Med Sci Monit 2022; 28:e938365
16 September 2022 : Review articleEffects of Physiotherapy on Rehabilitation and Quality of Life in Patients Hospitalized for COVID-19: A Rev...
Med Sci Monit In Press; DOI: 10.12659/MSM.938141
12 September 2022 : Clinical ResearchEffect of Vitamin D Concentration on Course of COVID-19
Med Sci Monit In Press; DOI: 10.12659/MSM.937741
29 August 2022 : Database AnalysisTranscriptome Analysis of Peripheral Blood Mononuclear Cells Response in Patients with Severe COVID-19 Reve...
Med Sci Monit 2022; 28:e937532
26 Sep 2022 : Clinical ResearchDistribution and Determinants of Plasma Homocysteine Levels in a Preconception Population: A Retrospective ...
Med Sci Monit In Press; DOI: 10.12659/MSM.937987
26 Sep 2022 : Clinical ResearchLatency and Interpeak Interval Values of Auditory Brainstem Response in 73 Individuals with Normal Hearing
Med Sci Monit In Press; DOI: 10.12659/MSM.937847
23 Sep 2022 : Review articleA Review of the Role of Ultrasound Radiomics and Its Application and Limitations in the Investigation of Th...
Med Sci Monit In Press; DOI: 10.12659/MSM.937738
Most Viewed Current Articles
30 Dec 2021 : Clinical ResearchRetrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...
Med Sci Monit 2021; 27:e935379
13 Nov 2021 : Clinical ResearchAcceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...
Med Sci Monit 2021; 27:e932788
08 Mar 2022 : Review articleA Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...
Med Sci Monit 2022; 28:e936292